XM does not provide services to residents of the United States of America.
E
E

EURTRY

News

Turkey updates euro rate for medicine prices to 21.6721 vs lira, 23.5% rise

Turkey updates euro rate for medicine prices to 21.6721 vs lira, 23.5% rise ISTANBUL, Oct 24 (Reuters) - Turkey increased the euro conversion rate of medicine prices at 21.6721 versus the lira as of October from previous 17.5483, corresponding to a 23.5% rise, according to a decision published on the country's official gazette on Thursday. The updated conversion rate is significantly lower than the market rate, with the lira trading at 36.7720 against the euro at 0709 GMT.
E

Traders aren't yet giving up on Turkish lira longs

BUZZ-COMMENT-Traders aren't yet giving up on Turkish lira longs Oct 4 (Reuters) - Turkey's September Consumer Price Index was quite a lot higher than expected, casting doubt on the viability of long lira positions, but many traders are still holding on to these positions via FX and options. The last Reuters poll in July suggested the CBRT would retain the 50bps interest rate before looking to trim it in Q4 , so Thursday's data might raise questions about the effectiveness of current economic pol
E
E
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.